ADDF invest in BrainScope for Alzheimer’s prediction biomarker
Pharmaceutical Technology
SEPTEMBER 20, 2023
The neurotech will receive the investment in Series B equity financing round to invest in Alzheimer’s disease research.
Sat.Sep 16, 2023 - Fri.Sep 22, 2023
324 
New RSV vaccines can be powerful tools, but rollout poses test
Bio Pharma Dive
SEPTEMBER 18, 2023
Public health officials, as well as drugmakers, are trying to raise awareness of RSV among older adults at risk, and convince them to get an additional respiratory shot alongside those for COVID and flu.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bioanalysis through automation: Our top four takeaways
Worldwide Clinical Trials
SEPTEMBER 20, 2023
Our team has been working diligently to find a way to revitalize how we use automation, and during WRIB this year, we presented a poster on “Revolutionizing Bioanalysis through Automation: Overcoming Challenges and Unlocking Potential.” In case you missed it, we’ve highlighted the top four takeaways: 1. Instrument Integration: At both hardware and software levels, our integration of multiple bioanalytical instruments created a total laboratory automation (TLA) system for ligand bindi
FDA approves Pfizer/BioNTech and Moderna’s adapted COVID-19 vaccines
Pharma Times
SEPTEMBER 18, 2023
The updated vaccines more closely target current circulating variants - News - PharmaTimes
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
Pharmaceutical Technology
SEPTEMBER 21, 2023
The US FDA has accepted Takeda’s NDA resubmission for TAK-721 for the short-term treatment of eosinophilic esophagitis (EoE), for review.
Startup AIRNA emerges from stealth to bring RNA editing to a rare disease
Bio Pharma Dive
SEPTEMBER 19, 2023
AIRNA is one of several biotechs to debut plans for target alpha-1 antitrypsin deficiency in recent years, with competitors such as AlveoGene, Wave Life Sciences and Arrowhead Pharmaceuticals.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
NICE recommends more genetic testing for links to ovarian cancer
Pharma Times
SEPTEMBER 20, 2023
Around 340,000 to 444,000 people in the UK carry one of nine pathogenic gene variants - News - PharmaTimes
Signal: Illumina leads $15m investment in Broken String Biosciences
Pharmaceutical Technology
SEPTEMBER 18, 2023
Embattled biotech giant Illumina has led series A funding into genomics mapping company Broken String Biosciences.
Orchard nears FDA decision on rare disease gene therapy
Bio Pharma Dive
SEPTEMBER 18, 2023
Three years after gaining European approval, Libmeldy is now under U.S. review with a deadline set for March.
Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals
pharmaphorum
SEPTEMBER 20, 2023
Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals Phil.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pfizer’s Vydura recommended by NICE for acute migraines
Pharma Times
SEPTEMBER 18, 2023
The treatment is the first oral GPCR receptor antagonist class recommended for NHS use - News - PharmaTimes
Kinnate Biopharma announces 70% layoffs and pipeline restructuring
Pharmaceutical Technology
SEPTEMBER 19, 2023
The company will suspend the development of three assets, considering strategic alternatives for two clinical programmes.
PBMs, PhRMA trade blame over drug costs in House hearing
Bio Pharma Dive
SEPTEMBER 19, 2023
Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second hearing on the PBM industry.
The fading generics industry and essential medicine supply
pharmaphorum
SEPTEMBER 19, 2023
The fading generics industry and essential medicine supply Mike.
NIH clinical trial for universal influenza vaccine begins
Pharma Times
SEPTEMBER 20, 2023
The universal vaccine could protect people against more strains of flu - News - PharmaTimes
FDA revises biosimilar guidelines for clearer drug labelling
Pharmaceutical Technology
SEPTEMBER 18, 2023
The FDA released a draft guidance giving advice on the correct labelling of biosimilar and interchangeable biosimilar products.
Genentech takes up a deal to make ‘molecular glue’ drugs
Bio Pharma Dive
SEPTEMBER 20, 2023
Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.
Leveraging technology for better women’s healthcare outcomes
pharmaphorum
SEPTEMBER 19, 2023
Leveraging technology for better women’s healthcare outcomes Mike.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Cancer Research UK invests £123m in Scotland
Pharma Times
SEPTEMBER 21, 2023
The investment will support research into cancer treatments and diagnosis - News - PharmaTimes
Pelican and Primordial Genetics merge to form biotech company Primrose Bio
Pharmaceutical Technology
SEPTEMBER 19, 2023
Pelican Technology has combined business with Primordial Genetics under a deal to create a private biotechnology company Primrose Bio.
Making us more human: Applying artificial intelligence to your clinical resourcing and talent acquisition strategy
Bio Pharma Dive
SEPTEMBER 18, 2023
With the rise of ChatGPT and artificial intelligence (AI), there are many ways the clinical staffing industry can use AI advantageously while removing the stigma that the rise of technology can be dehumanizing.
Novo Nordisk Foundation pumps $136M into new clinical cell therapy manufacturing 'hub' in Denmark
Fierce Pharma
SEPTEMBER 21, 2023
Looking to establish a “hub” in the cell therapy ecosystem, the Novo Nordisk Foundation is pumping 950 million Danish kroner (about $136 million) into a new clinical production site at the Technica | Looking to establish a “hub” in the cell therapy ecosystem, the Novo Nordisk Foundation is pumping 950 million Danish kroner (about $136 million) into a new clinical production site at the Technical University of Denmark (DTU) in Lyngby.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Evaxion validates its infectious disease AI vaccine platform
Pharma Times
SEPTEMBER 19, 2023
The platform identifies antigens to fight against bacterial infectious disease - News - PharmaTimes
FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408
Pharmaceutical Technology
SEPTEMBER 22, 2023
A Phase I trial exploring the gene therapy in patients with alpha-1 antitrypsin deficiency is expected to start in Q1 2024.
FDA approves GSK’s new bone cancer drug, helping validate a billion-dollar bet
Bio Pharma Dive
SEPTEMBER 18, 2023
The drug, known scientifically as momelotinib, is now cleared to treat myelofibrosis and will compete against rival medicines sold by Incyte and Bristol Myers Squibb.
Machine learning puts virtual drug screening into high gear
pharmaphorum
SEPTEMBER 22, 2023
Machine learning puts virtual drug screening into high gear Phil.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Evaxion and Afrigen Biologics to develop mRNA vaccine for gonorrhoea
Pharma Times
SEPTEMBER 22, 2023
The collaboration will utilise Evaxion’s EDEN-discovered antigen targets - News - PharmaTimes
Evaxion partners with Afrigen Biologics to develop mRNA gonorrhea vaccine
Pharmaceutical Technology
SEPTEMBER 21, 2023
The collaboration will use Evaxion’s EDEN platform to bring an AI-designed gonorrhea mRNA vaccine to the market.
AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors
Bio Pharma Dive
SEPTEMBER 22, 2023
Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.
Anthos Stops Mid-Stage Atrial Fibrillation Trial Due to ‘Unprecedented’ Efficacy
BioSpace
SEPTEMBER 17, 2023
After evidence of “overwhelming reduction” in bleeding compared to Bayer and J&J’s Xarelto, Anthos Therapeutics has ended its Phase II atrial fibrillation study for abelacimab ahead of schedule.
Let's personalize your content